维奈克拉联合治疗急性髓系白血病的疗效和预后因素分析
Analysis of the Efficacy and Prognosis Factors of Acute Myeloid Leukemia with a Combination Therapy of Venetoclax
任崇崇 1张婉婉 1吴庭恺 1刘蓓2
作者信息
- 1. 兰州大学第一临床医学院
- 2. 兰州大学第一医院血液内科,甘肃兰州 730000
- 折叠
摘要
目的:探讨维奈克拉(venetoclax,VEN)联合治疗急性髓系白血病(AML)的疗效和预后因素.方法:回顾性分析2020年3月至2023年4月在兰州大学第一医院接受VEN联合治疗的AML患者的临床资料,观察疗效及生存情况,分析其影响因素并评估安全性.结果:本研究共纳入74例AML患者,其中初治AML 43例,复发难治性AML(R/R AML)31例.43例初治AML患者的中位年龄为65岁,复合完全缓解(cCR)率为67.4％(29/43),客观缓解率(ORR)为72.1％(31/43),中位总生存期(OS)为17.3个月.31例R/R AML患者中位年龄为51岁,cCR率为38.7％(12/31),ORR为58.1％(18/31),中位OS为7.1个月.性别、VEN治疗前血细胞计数、基因突变和预后分层与能否获得cCR有关.未获得cCR是患者死亡的独立危险因素.结论:VEN联合治疗AML安全有效,其疗效和生存受分子生物学、细胞遗传学等因素影响.
Abstract
Objective:To explore the efficacy and prognosis factors of acute myeloid leukemia with a combination therapy of venetoclax.Methods:A retrospective analysis was performed on the clinical data of AML patients treated with a combination therapy of venetoclax from March 2020 to April 2023 in the First Hospital of Lanzhou University.The efficacy,adverse reactions and survival were observed,and the influencing factors were analyzed.Results:A total of 74 AML patients were included in this study,including 43 initially treated AML and 31 relapsed or refractory AML(R/R AML).The median age of 43 initially treated AML patients was 65 years old,the composite complete remission(cCR)rate was 67.4％(29/43),the objective response rate(ORR)was 72.1％(31/43),and the median overall survival(OS)was 17.3 months.The median age of 31 R/R AML patients was 51 years old,with a cCR rate of 38.7％(12/31),an ORR of 58.1％(18/31),and a median OS of 7.1 months.Sex,the blood cell count before VEN,gene mutation and prognosis stratification were related to whether to obtain cCR.Failure to obtain cCR was an independent risk factor for adverse outcomes.Conclusion:A combination therapy of venetoclax is safe and efficacious for AML.Its efficacy and survival are affected by molecular biology,cytogenetics and other factors.
关键词
维奈克拉/急性髓系白血病/疗效/生存Key words
venetoclax/acute myeloid leukemia/efficacy/survival引用本文复制引用
基金项目
甘肃省自然科学基金(18JR3RA356)
出版年
2024
NETL
NSTL
维普
万方数据